脊髓损伤患者的NG004 (SPROUT)
人类(FIH)临床试验,用于研究人类单克隆抗体NG004,在急性脊髓损伤(SCI)患者中固定管理
This is the FIH, multicenter, open-label, sequential, multiple ascending dose trial of NG004 in patients with acute incomplete cervical SCI. The trial will evaluate the safety, tolerability, and PK of 4 dose regimens of NG004, and will evaluate the maximum tolerated dose of NG004. The trial consists of Part A (the dose escalation) and Part B (the PK-confirmation at 2 dose levels from Part A).
研究概览
研究类型
注册 (估计的)
阶段
- 阶段1
联系人和位置
学习地点
-
-
-
Bayreuth、德国
- Klinik für Querschnittgelähmte, Klinikum Bayreuth
-
Halle、德国
- Zentrum für Rückenmarkverletzte und Klinik für Orthopädie, BG Klinikum Bergmannstrost
-
Heidelberg、德国
- Klinik für Paraplegiologie, Universitätsklinikum Heidelberg
-
Murnau am Staffelsee、德国
- Zentrum für Rückenmarksverletzte, Unfallklinik Murnau
-
-
-
-
-
Nottwil、瑞士
- Swiss Paraplegic Centre
-
Zurich、瑞士
- Universitätsklinik Balgrist
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Acute incomplete cervical SCI (Neurological level of injury C1 ≤ lesion ≤ C8) with confirmed classification of American Spinal Injury Association (ASIA) impairment scale (AIS) C-D at Screening
- 4-28 days post-injury
- No required mechanical ventilation or patients that not completely depend on mechanical ventilation
- Hemodynamically and clinical stable patient according to the acute SCI condition at baseline
Exclusion Criteria:
- Trauma caused by ballistic or other injury that directly penetrates the spinal cord including gunshot and knife wounds
- Multiple levels of clinically relevant spinal cord lesions
- Major brachial or lumbar plexus damage/trauma
- Significant head trauma or other injury that was, in the opinion of the investigator, sufficient to interfere with the assessment of the spinal cord function
- Other significant pre-existing or current severe systemic disease such as lung, liver (exception: history of uncomplicated Hepatitis A), gastrointestinal, cardiac, immunodeficiency (including anamnestic known HIV) or kidney disease; or active malignancy
- History of or an acute episode of Multiple Sclerosis or Guillain-Barre syndrome History of recent (6 months) meningitis or meningoencephalitis
- History of refractory epilepsy
- History of or current autoimmune disease
- Patients with uncontrolled bleeding diathesis and/or who require concomitant therapeutic anticoagulation and not related to SCI
- Presence of any unstable medical or psychiatric condition
- Drug dependence any time during the 6 month's preceding trial entry
- Pregnant or nursing women
- History of a life-threatening allergic or immune mediated reaction
- Patients with the presence of infection around the location where the spinal needle insertions are planned for applying the intrathecal injections
- Participation in any clinical investigation within 4 weeks prior to dosing or longer if required by local regulations
- Patients who are unconscious
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:不适用
- 介入模型:单组作业
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:NG004
|
repeated intrathecal injections of NG004 |
研究衡量的是什么?
主要结果指标
结果测量 |
大体时间 |
|---|---|
|
不良事件(AES),严重AE和不良药物反应的类型,频率,严重性和因果关系
大体时间:从治疗开始到6个月
|
从治疗开始到6个月
|
次要结果测量
结果测量 |
大体时间 |
|---|---|
|
血清中最大血浆浓度[CMAX]
大体时间:在剂量前和剂量后1、3、6、24、48小时测量的第一和最后一次鞘内注射之后。
|
在剂量前和剂量后1、3、6、24、48小时测量的第一和最后一次鞘内注射之后。
|
|
血清中的半衰期[T1/2]
大体时间:最后一次鞘内注射后6个月后
|
最后一次鞘内注射后6个月后
|
其他结果措施
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Effect on motor function as Change from Baseline in ISNCSCI upper extremities motor score (UEMS), according to the International Standards for the Neurological Classification of Spinal Cord Injury (ISNCSCI) protocol
大体时间:Baseline up to 6 months
|
The ISNCSCI bilateral Upper Extremity Motor Score (UEMS) is determined by examining the muscle function within each of the 5 myotomes encompassing arm and hand function on each side of the body. A score ranging from 0 to 5 can be given to each myotome tested resulting in a maximum score of 50. Higher values indicate better recovery. |
Baseline up to 6 months
|
|
Effect on daily life functioning according to change in Version III of the Spinal Cord Independence Measure (SCIM-III)
大体时间:Baseline to 6 months
|
The SCIM III questionnaire self-care score assesses activities of daily living including feeding, bathing, dressing, and grooming. The self-care score ranges 0-20. The higher scores correspond to better ability to carry out the self-care activities. |
Baseline to 6 months
|
合作者和调查者
调查人员
- 研究主任:Director of Clinical Research、NovaGo Therapeutics AG
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.